Sylvie Burnouf

A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.

Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease.

A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.

From tau phosphorylation to tau aggregation: what about neuronal death?

Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission.

Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology.

Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor.

Hippocampal BDNF expression in a tau transgenic mouse model.

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model.

Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.

Association between caffeine intake and age at onset in Huntington's disease.

From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?